Why Did Compass Pathways Stock Rocket Higher Today?

Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials ...
Fierce Biotech

Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...
BioSpace

Compass’ Psychedelic Shows Durability ‘In Spades’ as Path to FDA Clears

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
Clinical Trials Arena on MSN

Compass stock heads north on psychedelic’s Phase III TRD success

Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.

Compass' psychedelic-based depression treatment scores second late-stage study win

Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model Updates

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Compass Pathways Shares Rise After Psilocybin Therapy Achieves Trial Targets

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...
BioPharma Dive

Compass, with Phase 3 hits, ready to take psilocybin to the FDA

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.